Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Ultra-Low PSA Responses and Clinical Outcomes

Key Themes:

• Correlation between achieving PSA <0.02 ng/mL and clinical outcomes
• Impact on time to progression and radiographic progression-free survival (rPFS)
• Overall survival trends in relation to PSA response

Expert Insights:

• Dr Shore presented data demonstrating that patients achieving ultra-low PSA levels (<0.02 ng/mL) experienced improved clinical outcomes.

The analysis showed correlations between ultra-low PSA and important end points including time to progression, rPFS, and overall survival trends